Increasing utility of FeNO as a biomarker of type-2 inflammation in severe asthma
- PMID: 34181878
- DOI: 10.1016/S2213-2600(21)00170-3
Increasing utility of FeNO as a biomarker of type-2 inflammation in severe asthma
Conflict of interest statement
I have received honoraria for participating on Advisory Board meetings of GlaxoSmithKline, AstraZeneca, Roche, Novartis, Merck, Nocion, and Shionogi regarding treatments for asthma, chronic obstructive pulmonary disease, and chronic cough, and have also been renumerated for speaking engagements.
Comment in
-
Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis.Lancet Respir Med. 2021 Oct;9(10):1165-1173. doi: 10.1016/S2213-2600(21)00124-7. Epub 2021 Jun 25. Lancet Respir Med. 2021. PMID: 34181876
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
